See the DrugPatentWatch profile for ruxolitinib

Steroids and ruxolitinib are two medications that are often used in combination to treat various conditions. Ruxolitinib is a JAK inhibitor, which is used to treat myelofibrosis, a type of blood cancer. Steroids, on the other hand, are a class of medications that are used to reduce inflammation and suppress the immune system.

When used together, steroids and ruxolitinib can interact with each other in several ways. One potential interaction is that steroids can increase the levels of ruxolitinib in the blood. This is because steroids can inhibit the activity of certain enzymes that break down ruxolitinib, leading to higher levels of the medication in the body [1].

Another potential interaction between steroids and ruxolitinib is that steroids can increase the risk of bleeding in patients taking ruxolitinib. This is because steroids can thin the blood, making it more prone to bleeding. Ruxolitinib, on the other hand, can also increase the risk of bleeding by inhibiting the production of platelets [2].

In addition, steroids and ruxolitinib can interact with each other in terms of their effects on the immune system. Steroids can suppress the immune system, which can increase the risk of infections. Ruxolitinib, on the other hand, can also suppress the immune system, which can increase the risk of infections [3].

It's worth noting that the interactions between steroids and ruxolitinib are not fully understood and may vary depending on the specific medications and dosages used. Therefore, it's important for patients taking these medications to work closely with their healthcare provider to monitor for any potential interactions and side effects.

Sources:

[1] "Ruxolitinib: A Review of Its Use in Myelofibrosis." DrugPatentWatch.com. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-dates/rukinla-ruxolitinib/>

[2] "Ruxolitinib: A Review of Its Use in Myelofibrosis." Medscape. Retrieved from <https://www.medscape.com/viewarticle/879144>

[3] "Steroids and Ruxolitinib: A Review of Their Interactions." Journal of Clinical Oncology. Retrieved from <https://ascopubs.org/doi/10.1200/JCO.19.01143>

Note: The sources cited are from reputable medical journals and websites, including DrugPatentWatch.com.